IFNB1 and neoplasm: Indeed, in situ gene therapy followed by subcutaneous injection of naïve LLC cells resulted in greatly enhanced inhibition of the challenge tumor when the primary tumor had been treated with p19Arf + IFNβ rather than IFNβ alone.